KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacific Biosciences Of California (PACB) EBIT Margin (2016 - 2026)

Pacific Biosciences Of California has reported EBIT Margin over the past 16 years, most recently at 92.28% for Q4 2025.

  • For Q4 2025, EBIT Margin rose 29786.0% year-over-year to 92.28%; the TTM value through Dec 2025 reached 346.15%, down 3818.0%, while the annual FY2025 figure was 346.15%, 3818.0% down from the prior year.
  • EBIT Margin for Q4 2025 was 92.28% at Pacific Biosciences Of California, up from 101.13% in the prior quarter.
  • Over five years, EBIT Margin peaked at 92.28% in Q4 2025 and troughed at 1154.51% in Q1 2025.
  • A 5-year average of 252.04% and a median of 179.56% in 2021 define the central range for EBIT Margin.
  • On a YoY basis, EBIT Margin climbed as much as 37549bps in 2025 and fell as far as -94487bps in 2025.
  • Year by year, EBIT Margin stood at 179.56% in 2021, then plummeted by -77bps to 318.37% in 2022, then skyrocketed by 53bps to 150.02% in 2023, then plummeted by -160bps to 390.14% in 2024, then surged by 76bps to 92.28% in 2025.
  • Business Quant data shows EBIT Margin for PACB at 92.28% in Q4 2025, 101.13% in Q3 2025, and 112.79% in Q2 2025.